Delivery Order SPE2DB20D3111-SPE2DB25FA9EF
- Not listed
- The Defense Logistics Agency awarded a $1,687.48 delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for ProQuad vials with a completion date of August 29, 2025. This firm fixed-price, non-set-aside contract is being performed in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. As a child order under a larger contract vehicle, this delivery order leverages AmerisourceBergen's established relationships with DLA for pharmaceutical supply to...
- The Defense Logistics Agency awarded a $16,543.30 delivery order to AmerisourceBergen Drug Corp for ProQuad vials, a combination vaccine product, with a completion date of August 21, 2025. This competitive award (no set-aside used) was issued under a firm fixed-price structure and represents a child contract under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $3,374.88 to AmerisourceBergen Drug Corp for ProQuad vials on July 29, 2025, with an ultimate completion date of August 19, 2025. This firm fixed price, competitively awarded contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999. The delivery order will be fulfilled at AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a firm fixed price delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of ProQuad vials valued at $13,234.64 with a completion date of August 11, 2025. This non-competitive delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion comprehensive pharmaceutical support vehicle running through December 2026. The performance location is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for ProQuad vials valued at $2,740.40 with an ultimate completion date of August 19, 2025. This firm fixed price, competitively awarded delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The order will be performed at AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a $1,687.48 firm fixed price delivery order to AmerisourceBergen Drug Corp for ProQuad vials on August 19, 2025, with a completion date of September 10, 2025. This non-set-aside competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The place of performance is located in...
- The Defense Logistics Agency awarded a $5,062.32 delivery order to AmerisourceBergen Drug Corp for ProQuad vials under a firm fixed-price contract. The delivery order, which has an ultimate completion date of August 21, 2025, was awarded on July 31, 2025, with no set-aside designation. Performance will take place at the contractor's Corporate Office location in Conshohocken, Pennsylvania. ProQuad is a combination vaccine product, and this delivery order represents a routine pharmaceutical...
- The Defense Logistics Agency awarded a $1,654.33 firm fixed price delivery order to AmerisourceBergen Drug Corp for ProQuad vials on August 20, 2025, with a completion date of September 11, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.99 million and extending through December 2026. The order will be performed at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency awarded a delivery order valued at $5,372.90 to AmerisourceBergen Drug Corp for ProQuad vials on July 24, 2025, with an ultimate completion date of August 14, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitively awarded transaction for pharmaceutical supply to support federal medical procurement needs. The contract is performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, the company's...
- The Defense Logistics Agency awarded a delivery order valued at $1,670.90 to AmerisourceBergen Drug Corp for ProQuad vials, with an ultimate completion date of August 18, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the prime contractor. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- SPE2DB20D3111Indefinite Delivery Contract
- SPE2DB20D3111-SPE2DB25FA9EFDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for ProQuad vials valued at $1,687.48, with an ultimate completion date of September 23, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation to the pharmaceutical distributor's Corporate Office location in Conshohocken, Pennsylvania. The award represents a single transaction under AmerisourceBergen's existing contract vehicle with DLA for pharmaceutical and medical supply procurement. This delivery order is issued under AmerisourceBergen's $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and extending through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of medications, vaccines, and medical supplies to support military healthcare programs worldwide. The ProQuad vials delivery fulfills DLA's requirement for this combination vaccine product as part of the broader pharmaceutical prime vendor program supporting Defense Health Agency operations and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 9/2/25 |